Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone Hydrochloride Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Depot Naltrexone Treatment of Opioid Dependent Parolees

NCT00756990
View directory record Official record
Conditions
Opioid Dependence
Interventions
Depot Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Chronic Pain From Arthritis

NCT03008590
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 3, 2026, 2:18 PM EDT
Active, not recruiting Phase 4 Interventional

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

NCT06098079
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone-Bupropion (NB) Combination, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
140
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 3, 2026, 2:18 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Long-acting Naltrexone for Pre-release Prisoners

NCT02867124
View directory record Official record
Conditions
Opiate Addiction
Interventions
XR-NTX, place of residence, opioid treatment program
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 3, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

NCT00758966
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg, Naltrexone SR 32 mg
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
11
States / cities
National City, California • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

NCT01415895
View directory record Official record
Conditions
Back Pain, Lower Back Pain, Cervical Pain
Interventions
Naltrexone and Clonidine Combination, placebo
Drug
Lead sponsor
Annette C. Toledano MD
Industry
Eligibility
19 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Not applicable Interventional Results available

Fostering MAT Use in Justice Populations

NCT04363320
View directory record Official record
Conditions
Opioid-use Disorder, Recidivism
Interventions
NIATx Coaching, ECHO
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone and Hypoglycemia in Type 1 Diabetes

NCT01053078
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 3, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional Results available

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

NCT02137252
View directory record Official record
Conditions
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions
Naltrexone, Sugar Pill
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 3, 2026, 2:18 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

NCT02680847
View directory record Official record
Conditions
Moderate-severe Pain
Interventions
ALO-02
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 3, 2026, 2:18 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

NCT00419731
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Bupropion + Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

NCT02165930
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Naltrexone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation

NCT01677039
View directory record Official record
Conditions
Healthy
Interventions
Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Effective Treatment for Prescription Opioid Abuse

NCT00719095
View directory record Official record
Conditions
Prescription Opioid Dependence
Interventions
buprenorphine taper followed by naltrexone maintenance, Behavioral therapy
Drug · Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Results available

Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

NCT01625611
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Naltrexone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 3 Interventional

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence

NCT00167232
View directory record Official record
Conditions
Cocaine Dependence, Alcoholism
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Glioma Patients

NCT01303835
View directory record Official record
Conditions
Malignant Glioma
Interventions
LDN, Placebo
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

NCT01180647
View directory record Official record
Conditions
Opiate Dependence
Interventions
Extended-Release Naltrexone, Motivational Enhancement Counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

NCT04409041
View directory record Official record
Conditions
Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Low-Dose Naltrexone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 3, 2026, 2:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

NCT03539900
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 3, 2026, 2:18 PM EDT